ZELECIMENT BASIVARSEN

UNII:	T7PH26YY2C
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	ZELECIMENT BASIVARSEN
GSRS Full Record:	T7PH26YY2C i

2767191-74-0
DYNE-101
Fab-G1 VH-CH1 chain (1-227) [VH Musmus/Homsap (Mus musculus IGHV3-6*01 (84.5%) -(IGHD) -IGHJ2*01 (85.7%)L124>V (115)/Homo sapiens IGHV4-30-4*01 (82.8%) -(IGHD) -IGHJ4*01 (85.7%) L123>T (114), CDR-IMGT [9.7.12] (26-34.52-58.97-108)) (1-119) -Homo sapiens IGHG1*01 CH1-h(100%), G1m17 CH1 K120 (CH1 K120 (216) (120-217), hinge 1-10 (218-227)) (120-217)], (222-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (85.3%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3, A45.1(153), V101 (191) (108'-214') produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, non-glycosylated, substituted at N6 of 1 to 3 L-lysine residues with 1-{(5aRS,6SR,6aSR)-1-[(6S,9S)-1-amino-6-{[4-({[(6-{[all-P-ambo-2'-O,4'-C-methylene-P-thioadenylyl-(5'→3')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(5'→3')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(5'→3')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(5'→3')-2'-deoxy-P-thioadenylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thioadenylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thioguanylyl-(5'→3')-5-methyl-2'-O-(2-methoxyethyl)-P-thiocytidylyl-(5'→3')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(5'→3')-2'-O,4'-C-methylene-P-thioadenylyl-(5'→3')-5-methyl-2'-O,4'-C-methylene-5'-cytidylyl]oxy}hexyl)carbamoyl]oxy}methyl)pheny]carbamoyl}-1,8,11-trioxo-9-(propan-2-yl)-14,17,20-trioxa-2,7,10-triazadocosan-22-yl]-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl}-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oyl (basivarsen) groups
Immunoglobulin G1 Fab fragment, anti-(human and Macaca fascicularis transferrin receptors type 1) (human-Mus musculus monoclonal F5298 γ1-chain), disulfide with human-Mus musculus monoclonal F5298 κ-chain, N6-amide with DNA d(P-thio)((2′-O,4′-C-methylene)m5rC-(2′-O,4′-C-methylene)rA-[2′-O-(2-methoxyethyl)]rG-[2′-O-(2-methoxyethyl)]m5rC-G-C-C-C-A-C-C-A-[2′-O-(2-methoxyethyl)]rG-[2′-O-(2-methoxyethyl)]m5rU-(2′-O,4′-C-methylene)m5rC-(2′-O,4′-C-methylene)rA) 5′-[6-[[[[4-[[N-[3-[2-[2-[2-[(5aS,6R,6aR)-6-(18-carboxy-3-oxo-2,7,10,13,16-pentaoxa-4-azaoctadec-1-yl)-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazol-1-yl]ethoxy]ethoxy]ethoxy]-1-oxopropyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]amino]hexyl hydrogen phosphate]
ZELECIMENT BASIVARSEN [USAN]
Zeleciment basivarsen
immunoglobulin Fab G1-kappa (VH-CH1_L-kappa), anti-[Homo sapiens TFRC (transferrin receptor, TfR1, TFR1, CD71)], monoclonal antibody; substituted at N6 of lysine residues with basivarsen groups
immunoglobulin Fab G1-kappa (VH-CH1_L-kappa), anti-[Homo sapiens TFRC (transferrin receptor, TfR1, TFR1, CD71)], monoclonal antibody; substituted at N6 of lysine residues with basivarsen groups; Fab-G1 VH-CH1 heavy chain (1-227) [VH Musmus/Homsap (Mus musculus IGHV3-6*01 (84.5%) -(IGHD) -IGHJ2*01 (85.7%) L124>V (115)/Homo sapiens IGHV4-30-4*01 (82.8%) -(IGHD) -IGHJ4*01 (85.7%) L123>T (114), CDRIMGT [9.7.12] (26-34.52-58.97-108)) (1-119) -Homo sapiens IGHG1*01 (100%) CH1-h (100%), G1m17 CH1 K120 (CH1 K120 (216) (120-217), hinge 1-10 (218-227)) (120-227)], (222-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (85.3%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27-32.51-53.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3, A45.1(153), V101 (191) (108'-214')], produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, nonglycosylated; substituted at N6 of 1 to 3 L-lysine residues with 1-{(5aRS,6SR,6aSR)-1-[(6S,9S)-1-amino-6-{[4-({[(6-{[all-P-ambo-2'-O,4'-C-methylene-P-thioadenylyl-(5'→3')-5-methyl-2'-O,4'-C-methylene-P-thiocytidylyl-(5'→3')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(5'→3')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(5'→3')-2'-deoxy-P-thioadenylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thioadenylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-Pthiocytidylyl-(5'→3')-2'-deoxy-P-thiocytidylyl-(5'→3')-2'-deoxy-P-thioguanylyl-(5'→3')-5-methyl-2'-O-(2-methoxyethyl)-P-thiocytidylyl-(5'→3')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(5'→3')-2'-O,4'-C-methylene-P-thioadenylyl-(5'→3')-5-methyl-2'-O,4'-C-methylene-5'-cytidylyl]oxy}hexyl)carbamoyl]oxy}methyl)pheny]carbamoyl} -1,8,11-trioxo-9-(propan-2-yl)-14,17,20-trioxa-2,7,10-triazadocosan-22-yl]-1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d][1,2,3]triazol-6-yl}-3-oxo-2,7,10,13,16-pentaoxa-4-azanonadecan-19-oyl (basivarsen) groups
zeleciment basivarsen [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ZELECIMENT BASIVARSEN

Synonyms and Mappings

Resources